UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $5.85
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target from $6.5 to $5.85.
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target from $6.5 to $5.85.